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Abstract
We used the World Health Organization’s Composite International Diagnostic Interview to determine the prevalence, comor-
bidity, and correlates of lifetime and 12-month behavioral health disorders in a multisite cohort of 1027 women living with 
HIV in the United States. Most (82.6%) had one or more lifetime disorders including 34.2% with mood disorders, 61.6% 
with anxiety disorders, and 58.3% with substance use disorders. Over half (53.9%) had at least one 12-month disorder, 
including 22.1% with mood disorders, 45.4% with anxiety disorders, and 11.1% with substance use disorders. Behavioral 
health disorder onset preceded HIV diagnosis by an average of 19 years. In multivariable models, likelihood of disorders was 
associated with women’s race/ethnicity, employment status, and income. Women with 12-month behavioral health disorders 
were significantly more likely than their counterparts to engage in subsequent sexual and substance use HIV risk behaviors. 
We discuss the complex physical and behavioral health needs of women living with HIV.
Keywords Psychiatric epidemiology · Women living with HIV · Mental illness · Substance use disorder · Prevalence of 
behavioral health disorder
Resumen
Utilizamos la Entrevista Diagnóstica Internacional Compuesta de la Organización Mundial de la Salud para determinar 
la prevalencia, la comorbilidad y los correlatos de trastornos de salud conductual de la vida y de 12 meses en una cohorte 
multisitio de 1.027 mujeres que viven con VIH en los Estados Unidos. La mayoría (82.6%) tuvo uno o más trastornos en su 
vida, incluyendo 34.2% con trastornos del estado de ánimo, 61.6% con trastornos de ansiedad y 58.3% con trastornos por el 
uso de las sustancias. Más de la mitad (53.9%) tuvo al menos un trastorno en los últimos 12 meses, incluyendo 22.1% con 
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trastornos del estado de ánimo, 45.4% con trastornos de ansiedad y 11.1% con trastornos por el uso de las sustancias. El 
inicio del trastorno de salud conductual precedió el diagnóstico de VIH en un promedio de 19 años. En modelos multivari-
ables, la probabilidad de trastornos se asoció con la raza/etnia de las mujeres, el estado de empleo y los ingresos. Las mujeres 
con trastornos de salud conductual de 12 meses fueron considerablemente más probable que sus homólogas a participar en 
comportamientos de riesgo de VIH como el uso de las sustancias y conductas sexuales de riesgo. Discutimos las necesidades 
complejas de salud física y conductual de las mujeres que viven con el VIH.
Introduction
In the US, the prevalence of psychiatric disorders and 
substance use disorders among people living with HIV is 
thought to be high [1–3]. However, estimates typically are 
derived from small, non-representative samples because 
population-based studies are rare, and most research uses 
screening rather than full diagnostic assessment. Moreover, 
prior research has addressed a limited range of specific dis-
orders or diagnostic groupings, with few reports on a com-
prehensive array of psychiatric disorders and substance use 
disorders. The purpose of this study was to determine the 
prevalence, comorbidity and correlates of a full range of 
behavioral health disorders in a longitudinal multisite cohort 
of women living with HIV participating in the Women’s 
Interagency HIV Study or WIHS.
To date, the sole nationally representative study of 
behavioral health disorders among HIV-positive US adults 
is the 1996–1997 HIV Cost and Services Utilization Study 
(HCSUS) [4]. Using the Composite International Diagnos-
tic Interview (CIDI) Short Form, HCSUS participants were 
screened for major depression, dysthymia, generalized anxi-
ety disorder, and panic disorders in the past year [5]. Close 
to half screened positive for one or more of these psychiatric 
disorders (47.9% of the weighted sample). The full CIDI 
diagnostic interview was administered separately to a sub-
sample of the original cohort, and results were used to refine 
prevalence estimates [6] resulting in a 32.8% prevalence of 
any 12-month psychiatric disorder: 22.0% for major depres-
sion; 5.0% for dysthymia; 4.1% for generalized anxiety dis-
order; and 15.5% for panic disorder. While lower than those 
obtained by screening, these estimates were considerably 
higher than those found in a survey of the general popula-
tion which used the full CIDI and found prevalence rates of 
26.2% for any psychiatric disorder, 6.7% for major depres-
sion, 1.5% dysthymia, 3.1% generalized anxiety disorder, 
and 2.7% panic disorder [7, 8].
Clinical studies of smaller, non-representative samples 
report the prevalence for any current psychiatric disorder 
of 33–63% among HIV-positive adults [9–13]. Research 
on depressive disorders finds prevalence estimates ranging 
from 10 to 20% [11, 14]. Anxiety disorders also are preva-
lent, with estimates ranging from 5 to 15%, with the most 
common being generalized anxiety disorder and social anxi-
ety disorder [9, 14, 15].
Information about the prevalence of substance use disor-
ders among HIV-positive individuals is also lacking [1–3]. 
In the HCSUS CIDI-Short Form screening study, 50.1% of 
participants reported illicit drug use in the past year and 12% 
met criteria for drug dependence [5]. Close to a fifth (18.5%) 
met criteria for alcohol use disorders [4].
High rates of co-occurring psychiatric disorders and sub-
stance use disorders are reported among people living with 
HIV [10, 16, 17]. In the HCSUS, the 12-month prevalence 
of co-occurring disorders was 10% [18, 19]. Also in the 
HCSUS, multivariable analysis revealed that the presence 
of any psychiatric disorder was significantly associated with 
drug dependence, and vice versa [5]. However, there is very 
little information on co-occurrence of substance use disor-
ders with specific psychiatric syndromes, which inhibits our 
understanding of how these conditions interact, and their 
impact on HIV transmission behaviors and outcomes [20].
Turning next to HIV-positive women, a longitudinal 
multisite study of 1223 HIV-infected birth mothers found 
that 32% screened positive for psychiatric disorder, 9% for 
substance use disorder, and 35% for psychiatric disorder 
and/or substance use disorder [21]. Another study exam-
ined electronic medical records of HIV-positive patients 
in California, including 738 women, in which psychiatric 
disorder and substance use disorder diagnoses were based 
on clinician judgment and patient self-report [22]. In this 
study, 50% of female patients had a documented psychiatric 
disorder, including 25% with a mood disorder, 16% with 
an anxiety disorder and 12% with a substance use disorder. 
Among 1710 participants in the longitudinal multisite HIV-
positive WIHS cohort, 55% met criteria for probable depres-
sion [23] and they also reported high rates of alcohol [24] 
and substance use [25]. These comorbidities often occur in 
a context of poverty, trauma, housing instability, caregiving 
demands, racial/ethnic discrimination, and multiple health 
needs [26–28].
A number of studies have documented associations 
between behavioral health disorders and engaging in HIV 
transmission behaviors [29, 30]. These include sexual risk 
behaviors such as unprotected sex [31], having multiple 
sex partners [32], and receptive anal intercourse [33]. Also 
included are drug-related risk behaviors such as sharing 
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needles [34], and exchanging sex for drugs, money or other 
material items [34, 35]. An even greater likelihood of HIV 
risk behaviors has been observed among people with co-
occurring substance use disorders and psychiatric disorders 
[36–38], including major depressive disorder [39] and post-
traumatic stress disorder [40]. Moreover, while awareness 
of one’s HIV positive serostatus appears to decrease the 
likelihood of engaging in risk behaviors [41] even among 
those with psychiatric and/or substance use disorders [42], 
a noteworthy proportion of individuals living with HIV con-
tinue to engage in high-risk sex and drug use behaviors [43], 
creating opportunities for viral transmission to uninfected 
individuals [44].
Given the foregoing research findings and the remaining 
gaps in our knowledge, the present study addressed three 
major research questions. First, what are the lifetime and 
12-month prevalence and severity of a full range of DSM-IV 
disorders in a multisite study cohort of women living with 
HIV, and what syndromes are most frequently comorbid? 
Second, what are the individual correlates associated with 
psychiatric disorders and substance use disorders among 
these women? And third, are specific behavioral health dis-
orders, including co-occurring conditions, associated with 
a greater likelihood of engaging in HIV risk behaviors, con-
trolling for confounding factors?
Methods
Study Participants
The WIHS is a multisite cohort study of women living with 
or at risk of acquiring HIV infection recruited in the mid-
1990s at six US sites: Brooklyn, Bronx, Chicago, Los Ange-
les, San Francisco/Bay Area, and Washington, DC. Details 
of the WIHS cohort and study design can be found in prior 
publications [45, 46].
For this nested study, inclusion criteria were being an 
active HIV-positive WIHS participant, able to understand 
spoken English, and capable of completing an in-person 
assessment. From 2010 through 2013, 1213 English-
speaking women were approached and 1033 consented to 
participate (85.2%), providing written informed consent 
using procedures approved by the University of Illinois at 
Chicago (UIC) Institutional Review Board (IRB), and the 
IRBs at each study site. Data for this analysis include 1027 
women, representing 74.2% of the 1385 who were active as 
of 2010. The remaining 358 women were not included for 
the following reasons: unfinished interviews (n = 6); active 
refusals (n = 60); passive refusals whom we were unable 
to locate or schedule (n = 126); and exclusively Spanish-
language speakers (n = 166). Comparisons between the 
1027 study participants and the remaining 358 found no 
significant differences in age, education, income, marital 
status, CD4 + cell count, HIV-1 viral load, or use of com-
bination antiretroviral therapy (cART). However, compared 
to the remaining 358 non-participants, a larger proportion 
of study completers were African American (78.4% vs. 
64.4% of non-completers, Chi square = 13.91, p < 0.001), 
and not employed (68.2% vs. 55.5% of non-completers, Chi 
square = 11.71, p = 0.001). At all but one site, response 
rates ranged from 71 to 89%, with the remaining site (Los 
Angeles) having a low response rate of 40% due to the high 
concentration of Spanish-only speakers.
Measures
WIHS research interviewers from each site completed 3 days 
of training on the use of the World Health Organization 
CIDI 3.0 Auto Version, a comprehensive, fully standardized 
battery that assessed disorders according to the criteria of 
the DSM-IV, hereafter referred to as the WMH-CIDI [47]. 
Training was provided by either the University of Michigan’s 
WHO-designated WMH-CIDI training center or by WHO-
trained UIC research staff. Interviews were administered 
via laptop software programmed with skip patterns, error 
screening, and consistency checks. A randomly selected 5% 
of respondents were contacted via telephone by the UIC 
study manager following the interview, to verify interview 
process and completion.
Participant age, race/ethnicity, education, employment, 
income, marital status, study site, and CD4+ cell count were 
ascertained from the WIHS semiannual study visit closest to 
the WMH-CIDI assessment. Participant risk behaviors were 
assessed at up to 6 semiannual visits following the WMH-
CIDI assessment. HIV sexual risk behavior was defined as 
exchanging sex for money/drugs/shelter, multiple current 
male partners, or receptive anal sex; and substance use risk 
behavior was defined as use of any illicit drug or high risk 
drinking defined as consumption of > 7 standard alcoholic 
drinks per week in accordance with the National Institute on 
Alcohol Abuse and Alcoholism [48].
Statistical Analysis
Frequency distributions and cross-tabulations were used to 
calculate prevalence, severity, and comorbidity of behav-
ioral health diagnoses in the WIHS cohort and the 2003 
National Comorbidity Survey Replication (NCS-R) women’s 
cohort. Prevalence and standard errors in the NCS-R data 
were calculated using the study documentation manual’s 
survey strata, clusters, and weights [49]. Adjusted logistic 
regression analysis examined associations between partici-
pant characteristics and behavioral health disorders. Ran-
dom effects logistic regression models (RRM) analyzed the 
prospective relationships between 12-month diagnoses and 
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HIV sexual and substance use risk behaviors. Analyses were 
conducted in IBM SPSS Statistics 23 and SAS 9.4.
Results
Lifetime DSM‑IV Disorders and Age of Onset
Characteristics of the study participants are shown in 
Table 1. Table 2 presents the lifetime prevalence of DSM-
IV disorders in our study population and compares it to that 
of the US adult women’s general household population in the 
NCS-R. As shown at the bottom of column 1, the majority 
of our study population (82.6%) reported a lifetime DSM-IV 
disorder versus just under half of the general US women’s 
population (45.7%) shown in column 2. Prevalence of life-
time mood disorders in the study population was consider-
ably higher than that of the general population (34.2% vs 
23.7%) as were anxiety disorders (61.6% vs 37.0%), and 
substance use disorders, which were 6 times more likely 
in the study group versus the general population (58.3% vs 
8.8%). The most common specific lifetime disorders were 
drug abuse (49.4%), major depressive disorder (32.4%), and 
posttraumatic stress disorder (PTSD) (29.8%).
The average age of onset for different DSM-IV disorders 
is presented in column 3 of Table 2. The vast majority of 
mood disorders, anxiety disorders, and substance use dis-
orders had an average age of onset in the early- to mid-20s. 
The exceptions to this are earlier onset for several anxiety 
disorders including specific phobia (9.5 years of age), social 
phobia (13.6 years), and agoraphobia (16.8 years). Also, by 
definition, childhood separation anxiety disorder has an aver-
age age of onset in childhood, at 8.4 years.
The average age of HIV diagnosis for those with particu-
lar disorders is presented in column 4. Regardless of type of 
psychiatric disorder or substance use disorder, the average 
age at HIV diagnosis was in the early 30s, with the average 
age being earliest for those with panic disorder (31.7 years), 
obsessive–compulsive disorder (OCD) (31.7 years), and 
adult separation anxiety disorder (31.4  years), and lat-
est for social phobia (33.3  years), generalized anxiety 
disorder (33.1), and all of the substance use disorders 
(all > 33.3 years of age).
For the large majority of participants (95.5%) DSM-IV 
disorder onset preceded HIV diagnosis, and column 5 pre-
sents the average number of years between disorder onset 
and HIV diagnosis for this group. On average, mood disor-
der onset was 15.83 years prior to HIV diagnosis; anxiety 
disorder onset was 22.11 years prior to HIV diagnosis; and 
substance use disorder onset pre-dated HIV diagnosis by 
14.03 years. Among the minority of women (4.5%) whose 
HIV diagnosis predated their DSM-IV disorder onset, as 
shown in column 6, onset for mood disorders was an average 
of 8.68 years after HIV diagnosis; onset for anxiety disorders 
was 9.47 years after HIV diagnosis; and onset of substance 
use disorders occurred earliest, an average of 6.80 years after 
HIV diagnosis.
12‑Month DSM‑IV Disorders and Severity
Turning next to 12-month DSM-IV disorders, Table 3 pre-
sents their prevalence and severity in the WIHS cohort 
and corresponding information regarding the US women’s 
general household population in the NCS-R. Mood disor-
der prevalence in the WIHS cohort was 22.1% compared to 
10.8% in the general women’s population. Anxiety disor-
der prevalence was 45.4% in the WIHS compared to 23.2% 
in the general population, substance use disorders were 5 
times as prevalent in the WIHS compared to the general 
women’s population (11.1% vs. 2.2%). The most common 
mood disorder was major depressive disorder (20.0%). 
The most common anxiety disorders were specific phobias 
(22.1%), PTSD (16.6%), and social phobia (13.9%). Among 
substance use disorders, drug abuse with or without depend-
ence (5.0%) was more common than alcohol abuse with or 
without dependence (2.5%). Specific disorders with notice-
ably higher prevalence (i.e., 3 or more times) among women 
living with HIV than the general women’s population were 
dysthymia, bipolar disorders, agoraphobia, OCD, PTSD, and 
drug abuse.
Among women with 12-month disorders (bottom row 
of Table 3 columns 3–5), over half (57.6%) had at least 
one classified as serious, 17.2% as moderate, and 25.1% 
as mild in terms of highest severity level. Mood disorders 
had the highest percentage of serious classifications (81.1% 
of women with any mood disorder had at least one serious 
mood disorder), followed by anxiety disorders (51.1%), and 
substance use disorders (47.4%). Again in column 3, the spe-
cific mood disorder with the highest percentage of serious 
classifications was dysthymia (88.2%); the specific anxiety 
disorder with the highest percentage of serious classifica-
tions was panic disorder (73.3%); and the substance use dis-
order with the highest percentage of serious classifications 
was alcohol abuse (68.0%).
Regarding number of 12-month disorders (Table 3), over 
two-fifths (22.6%) of WIHS study participants had three 
or more disorders, compared to only 6.6% in the general 
women’s population; 11.1% of WIHS participants had 2 
disorders, compared to 6.1% in the general population, and 
20.2% had one disorder compared to 15.1% in the general 
population. In addition, as shown in the 3rd column, there 
was a positive relationship between severity and multiple 
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disorders. Here, among women with three or more disorders, 
84.9% had at least one disorder classified as serious on the 
severity scale, 58.8% of women with two disorders had at 
least one serious disorder, and 26.4% of women with only 1 
disorder had a serious disorder.
Comorbidity of Lifetime and 12‑Month Disorders
Comorbid disorders were common (not shown) for both 
lifetime and 12-month disorders. Lifetime mood disorders 
had the highest rate of comorbidity. Here, the large majority 
Table 1  Demographic and 
clinical characteristics of study 
population (n = 1027)
SD standard deviation, DSM-IV diagnostic and statistical manual of mental disorders, 4th edition
n = 1027
Mean (SD) or %(n)
Age, years 48.1 (8.7)
Age, quartiles (%)
 27–39 years 16.9 (174)
 40–49 years 40.1 (412)
 50–59 years 34.5 (354)
 60 + years 8.5 (87)
Race (%)
 White 17.1 (176)
 Black 78.4 (805)
 Asian 1.0 (10)
 Native American 0.4 (4)
 Other 3.1 (32)
Hispanic Ethnicity (%) 18.8 (193)
Education completed (%)
 0–11 years 33.1 (339)
 12 years 31.9 (327)
 13–15 years 26.9 276)
 16 + years 8.1 (84)
Employed full or part-time (%) 31.8 (327)
Annual household income ≤ $12,000 (%) 48.7 (466)
Marital Status (%)
 Married/cohabiting 36.9 (379)
 Previously married 31.1 (319)
 Never married 32.0 (329)
Site (%)
 Brooklyn, NY 25.2 (259)
 Bronx, NY 17.3 (178)
 Chicago, IL 14.2 (146)
 Los Angeles, CA 11.7 (120)
 San Francisco, CA 15.0 (154)
 Washington, DC 16.6 (170)
Taking combination antiretroviral therapy (cART) (%) 87.0 (893)
CD4 cell count (%)
 < 200 mm3 11.8 (121)
 200+ mm3 88.2 (906)
HIV RNA viral load (%)
 > 200 copies/mL 28.8 (295)
 ≤ 200 copies/mL 71.2 (731)
Engaged in HIV risk behaviors over 3 years post-DSM-IV diagnostic assessment (%)
 Risky sexual behaviors 16.2 (166)
 Risky substance use behaviors 38.1 (390)
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of women (87.2%) with a lifetime mood disorder also had 
a lifetime anxiety disorder, and over two-thirds (68.4%) of 
those with a lifetime mood disorder also had a lifetime sub-
stance use disorder. In contrast, less than half of women 
with lifetime anxiety disorders or substance use disorders 
had co-occurring lifetime mood disorders (48.3% and 40.1% 
respectively). In addition, lifetime anxiety disorders and 
substance use disorders were often comorbid, with 65.9% 
and 69.6% of each comorbid with the other, respectively. 
Similarly, 12-month mood disorders had the highest rate 
of comorbidity. Here, 79.7% of those with 12-month mood 
disorders also had 12-month anxiety disorders. However, 
12-month mood disorders were less frequently comorbid 
with 12-month substance use disorders (20.3%) given the 
relatively low prevalence of 12-month substance use disor-
ders. Similar to lifetime rates, 38.8% of those with 12-month 
anxiety disorders also had co-occurring 12-month mood dis-
orders, and 40.4% of those with 12-month substance use 
disorders also had 12-month mood disorders. The frequent 
co-occurrence of 12-month anxiety disorders and substance 
Table 2  Lifetime prevalence of DSM-IV disorders in the study population and general US women’s population, and age of onset of DSM-IV dis-
orders and HIV diagnosis in the study population (N = 1027)
SE standard error, w/wo with or without, DSM-IV diagnostic and statistical manual of mental disorders, 4th edition
a National Comorbidity Survey Replication (NCS-R) [49]
b From published NCS-R results. This disorder is not available in NCS-R data and is therefore excluded from summary prevalence calculations 
(e.g., any mood, anxiety, substance use or DSM-IV disorders)
DSM-IV diagnostic 
category
Study population 
prevalence % 
(SE)
General US wom-
en’s  populationa 
prevalence % [SE)
Average age of 
onset, in years
Average age of 
HIV diagnosis, in 
years
Average # years 
disorder preceded 
HIV diagnosis 
(95.5%)
Average # years HIV 
diagnosis preceded 
disorder (4.5%)
Mood disorders
 Major depressive 
disorder
32.4 (1.5) 22.9 (0.6) 20.04 32.35 15.94 8.62
 Dysthymia 9.9 (0.9) 5.1 (0.4) 19.52 32.18 16.66 6.28
 Bipolar I and II 
disorders
6.6 (0.8) 2.4 (0.3) 24.28 32.16 13.91 9.08
Any mood disorder 34.2 (1.5) 23.7 (0.6) 20.19 32.46 15.83 8.68
Anxiety disorders
 Panic disorder 9.0 (8.9) 6.2 (0.3) 23.83 31.72 14.76 9.75
 Agoraphobia 6.2 (0.7) 2.9 (0.3) 16.80 32.50 20.16 8.89
 Specific phobia 28.0 (1.4) 15.8 (0.6) 9.54 32.34 24.11 8.83
 Social phobia 19.7 (1.2) 13.0 (0.6) 13.65 33.34 21.34 8.76
 Generalized anxi-
ety disorder
13.2 (1.0) 9.9 (0.4) 24.44 33.13 16.52 10.11
 Posttraumatic 
stress disorder
29.8 (1.4) 9.7 (0.7) 23.68 32.29 14.53 8.38
 Obsessive–com-
pulsive disorder
16.0 (1.1) 3.1 (0.5)b 20.02 31.69 17.92 8.66
 Separation disor-
der (as child)
10.7 (1.0) 5.4 (0.5) 8.44 32.94 24.51 N/A
 Separation disor-
der (as adult)
15.9 (1.1) 7.4 (0.3) 26.78 31.36 12.74 8.60
Any anxiety dis-
order
61.6 (1.5) 37.0 (1.2) 13.19 32.64 22.11 9.47
Substance use disorders
 Alcohol w/wo 
dependence
19.6 (1.2) 7.5 (0.5) 22.88 33.47 13.88 8.27
 Drug abuse w/wo 
dependence
49.4 (1.6) 4.8 (0.4) 20.43 33.52 14.07 5.49
Any substance use 
disorder
58.3 (1.5) 8.8 (0.5) 20.99 33.54 14.03 6.80
Any DSM-IV 
disorder
82.6 (1.2) 45.7 (1.1) 13.96 33.01 20.20 6.49
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use disorders also was observed, since 61.4% of those with 
12-month substance use disorders had comorbid 12-month 
anxiety disorders.
Individual Correlates of Lifetime and 12‑Month 
Disorders
In multivariable logistic regression analysis (Table 4) with 
all individual characteristics entered (age, race/ethnic 
group, education, employment, income, marital/cohabit-
ing status, CD4+ cell count) and controlling for study site, 
lifetime mood disorder was less likely among women who 
were working than not working [odds ratio (95% confidence 
interval) OR 0.7 (0.5–1.0)]. Lifetime anxiety disorder also 
was less likely among women who were working than not 
working [OR 0.6 (0.4–0.8)], and more likely among women 
with CD4 cell counts higher than 200 [OR 1.5 (1.0–2.3)]. 
Lifetime substance use disorder was significantly more likely 
among women 40 years or older compared to those under 
age 40 [age 40–49 years OR 2.2 (1.5–3.3); age 50–59 OR 4.1 
(2.6–6.3); age 60 + OR 2.0 (1.1–3.7)]. Lifetime substance 
use disorder was less likely among Hispanic women [OR 
0.4 (0.4–0.7)] and women in Other race/ethnic groups than 
White women [OR 0.4 (0.2–0.9)]; less likely among women 
Table 3  12-Month prevalence of DSM-IV disorders in the study population and general United States women’s population, and DSM disorder 
severity in the study population (n = 1027)
SE standard error, N/A not available, w/wo with or without, DSM-IV diagnostic and statistical manual of mental disorders, 4th edition
a National Comorbidity Survey Replication (NCS-R) [49]
b Severity defined by: work disability, substantial role limitation or impairment, serious violence, or serious suicide attempt
c Percentages in the three severity columns are reported as proportions of all cases and sum to 100% across each row
d From published NCS-R results. This disorder is not available in NCS-R data and is therefore excluded from summary prevalence calculations 
(e.g., any mood, anxiety, substance use or DSM-IV disorders)
DSM-IV diagnostic category Study population 
prevalence
n = 1027 % (SE)
General US women’s 
 populationa prevalence % 
(SE)
Severityb of disorder in study  populationc
n = 1027
Serious % (SE) Moderate % (SE) Mild % (SE)
Mood disorders
 Major depressive disorder 20.0 (1.2) 10.2 (0.5) 80.0 (2.8) 14.6 (2.5) 5.4 (1.6)
 Dysthymia 9.9 (0.9) 2.9 (0.2) 88.2 (3.2) 7.9 (2.7) 4.0 (1.9)
 Bipolar I and II disorders 5.2 (0.7) 1.5 (0.2) 60.4 (6.8) 15.1 (5.0) 24.5 (6.0)
Any mood disorder 22.1 (1.3) 10.8 (0.5) 81.1 (2.6) 14.1 (2.3) 4.8 (1.4)
Anxiety disorders
 Panic disorder 5.8 (0.7) 3.8 (0.3) 73.3 (5.7) 20.0 (5.2) 6.7 (3.2)
 Agoraphobia 4.8 (0.7) 1.6 (0.2) 63.3 (6.9) 14.3 (5.1) 22.4 (6.0)
 Specific phobia 22.1 (1.3) 11.7 (0.5) 19.4 (2.6) 42.3 (3.3) 38.3 (3.2)
 Social phobia 13.9 (1.1) 7.8 (0.5) 60.8 (4.1) 18.2 (3.2) 21.0 (3.4)
 Generalized anxiety disorder 7.9 (0.8) 5.2 (0.3) 65.4 (5.3) 13.6 (3.8) 21.0 (4.5)
 Posttraumatic stress disorder 16.6 (1.2) 5.2 (0.4) 47.4 (3.8) 18.1 (3.0) 34.5 (3.6)
 Obsessive–compulsive dis. 8.1 (0.8) 1.8 (0.5)d 54.2 (5.5) 14.5 (3.9) 31.3 (5.1)
 Separation disorder (child) 1.5 (0.4) N/A 66.7 (12.6) 13.3 (9.1) 20.0 (10.7)
 Separation disorder (adult) 5.8 (0.1) 2.1 (0.2) 70.0 (5.6) 13.3 (4.4) 16.7 ((4.8)
Any anxiety disorder 45.4 (1.6) 23.2 (0.8) 51.1 (2.3) 19.5 (1.8) 29.4 (2.1)
Substance disorders
 Alcohol abuse w/wo dep 2.5 (0.5) 1.8 (0.3) 68.0 (9.5) 28.0 (9.2) 4.0 (4.0)
 Drug abuse w/wo dep 5.0 (0.7) 0.7 (0.1) 66.7 (6.7) 15.7 (5.1) 17.6 (5.4)
Any substance disorder 11.1 (1.0) 2.2 (0.3) 47.4 (4.7) 19.3 (3.7) 33.3 (4.4)
# of DSM-IV disorders
 1 disorder 20.2 (1.2) 15.1 (0.7) 26.4 (3.1) 18.8 (2.7) 54.8 (3.4)
 2 disorders 11.1 (1.0) 6.1 (0.4) 58.8 (4.6) 26.3 (4.1) 14.9 (3.4)
 3 + disorders 22.6 (1.3) 6.6 (0.4) 84.9 (2.3) 11.6 (2.1) 3.4 (1.2)
Any DSM-IV disorder 53.9 (1.6) 27.8 (0.9) 57.6 (2.1) 17.2 (1.6) 25.1 (1.8)
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with highest levels of education compared to those with the 
least education [16 + years OR 0.4 (0.2–0.8)]; less likely 
among women who were working compared to those not 
working [OR 0.7 (0.5–0.9)]; and less likely among women 
with higher income > = $12,000 than lower income [OR 
0.7 (0.5–0.9)].
Also in Table 4, 12-month mood disorder was less likely 
among Black women [OR 0.5 (0.3-0.9)] and Hispanic/Latina 
women [OR 0.5 (0.3–0.9)]; less likely among employed 
women than those not working [OR 0.4 (0.2–0.6)]; and less 
likely among women with higher income (i.e., > = $12,000) 
than lower income [OR 0.6 (0.4–0.9)]. Anxiety disorder 
was less likely among women 60 + years old compared to 
those < 40 years old [OR 0.4 (0.2–0.8)]; less likely among 
those with a high school or equivalent education compared to 
those with less education [OR 0.7 (0.5–0.9)]; and less likely 
Table 4  Multivariable sociodemographic and clinical correlates of lifetime and 12-month DSM-IV diagnostic categories, controlling for site 
(N = 1027)
OR odds ratio, CI confidence interval
+ p < 0.10, *p < 0.05, **p < 0.01, ***p < 0.001
Models adjusted for study site
DSM-IV diagnostic and statistical manual of mental disorders, 4th edition
Sociodemographic 
correlates
DSM-IV cases, odds ratios (95% CI)
Lifetime 12-Month
Mood disorder
OR (95% CI)
Anxiety disorder
OR (95% CI)
Substance use 
disorder
OR (95% CI)
Mood disorder
OR (95% CI)
Anxiety disorder
OR (95% CI)
Substance use disorder
OR (95% CI)
Age, years
 27–39 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
 40–49 1.4 (0.9–2.1) 1.0 (0.6–1.4) 2.2 (1.5–3.3)*** 1.3 (0.8–2.2) 0.8 (0.6–1.2) 1.2 (0.6–2.4)
 50–59 1.2 (0.8–1.9) 1.4 (0.9–2.1) 4.1 (2.6–6.3)*** 1.3 (0.8–2.2) 1.1 (0.7–1.6) 1.2 (0.6–2.6)
 60+  0.7 (0.4–1.4) 0.7 (0.4–1.2) 2.0 (1.1–3.7)* 0.7 (0.3–1.5) 0.4 (0.2–0.8)* 0.4 (0.1–1.4)
Race/ethnicity
 Non-Hispanic 
White
1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
 Non-Hispanic Black 0.7 (0.5–1.1) 1.0 (0.7–1.6) 0.7 (0.4–1.1)+ 0.5 (0.3–0.9)* 1.0 (0.7–1.5) 0.5 (0.3–0.9)*
 Hispanic 1.1 (0.6–1.8) 1.5 (0.9–2.4) 0.4 (0.2–0.7)** 0.5 (0.3–0.9)* 1.2 (0.8–2.0) 0.4 (0.2–0.8)*
 Other 1.2 (0.6–2.7) 0.5 (0.2–1.1)+ 0.4 (0.2–0.9)* 0.8 (0.3–2.0) 0.7 (0.3–1.5) 0.4 (0.1–1.6)
Education completed (years)
 0–11 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
 12 1.0 (0.7–1.4) 0.8 (0.6–1.1) 0.9 (0.6–1.3) 1.0 (0.7–1.5) 0.7 (0.5–0.9)* 0.8 (0.5–1.5)
 13–15 1.3 (0.9–1.8) 0.9 (0.6–1.2) 0.8 (0.6–1.2) 1.1 (0.7–1.7) 0.8 (0.6–1.1) 1.0 (0.5–1.7)
 16+ 0.9 (0.5–1.7) 1.0 (0.6–1.7) 0.4 (0.2–0.8)** 0.8 (0.4–1.7) 0.8 (0.5–1.4) 0.7 (0.2–1.9)
Work status
 Not working 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
 Working (part or 
full-time)
0.7 (0.5–1.0)* 0.6 (0.4–0.8)** 0.7 (0.5–0.9)* 0.4 (0.2–0.6)*** 0.5 (0.4–0.7)*** 0.6 (0.3–1.1)+
Income
 ≤ 12,000 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
 > 12,000 0.8 (0.6–1.1) 0.9 (0.6–1.2) .07 (0.5–0.9)* 0.6 (0.4–0.9)* 0.9 (0.6–1.2) 0.4 (0.2–0.6)***
Marital status
 Married/cohabiting 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
 Previously married 1.0 (0.7–1.4) 1.3 (0.9–1.8) 1.0 (0.7–1.4) 1.1 (0.7–1.6) 1.4 (1.0–1.9)+ 0.7 (0.4–1.2)
 Never married 1.0 (0.7–1.4) 1.3 (0.9–1.8) 1.1 (0.8–1.6) 1.2 (0.8–1.8) 1.2 (0.9–1.7) 1.4 (0.8–2.3)
CD4 cell count, %
 < 200 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference) 1.0 (reference)
 200+ 1.4 (0.9–2.2) 1.5 (1.0–2.3)* 1.1 (0.7–1.7) 1.2 (0.7–1.9) 1.5 (1.0–2.2)+ 0.7 (0.4–1.2)
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among those who were working compared to not working 
[OR 0.5 (0.4–0.7)]. Substance use disorders were less likely 
among Black women [OR 0.5 (0.3–0.9)] and Hispanic/Latina 
women [OR 0.4 (0.2–0.8)], and less likely among women 
with higher income [OR 0.4 (0.2–0.6)] than lower income.
Association of 12‑Month Disorders with Subsequent 
HIV Risk Behaviors
Our final research question was whether HIV-positive 
women with DSM-IV disorders were more likely to engage 
in HIV risk behaviors than those without disorders, and 
whether specific disorders or disorder combinations were 
associated with greater risk. In random effects logistic 
regression models adjusted for time, age, race (Latina or 
White vs. Black), education (< high school), and study 
site, we found significant associations between diagnosis 
of 12-month psychiatric disorders or substance use disor-
ders, as well as their co-occurrence, and the likelihood of 
engaging in subsequent sexual HIV risk behaviors (Table 5). 
Associations were particularly strong for women with mood 
disorders (major depression, dysthymia, bipolar disorders) 
and substance use disorders (alcohol or drug abuse/depend-
ence). For example, compared to their counterparts, women 
with 12-month bipolar disorders were over 13 times as likely 
[OR 13.6 (4.1–45.3)] and those with drug abuse disorders 
over 14 times as likely [OR 14.3 (4.3–47.1)] to engage in 
sexual risk behaviors in the ensuing 3 years. There also were 
Table 5  Results of random 
effects logistic regression 
models showing the prospective 
relationship of 12-month DSM-
IV mood, anxiety and substance 
use disorders to subsequent 
HIV risk behaviors over 3 years 
(n = 1024 women, n = 4488 
study visits)
OR odds ratio, CI confidence interval, DSM-IV diagnostic and statistical manual of mental disorders, 4th 
edition
*p < 0.05, **p < 0.01, ***p < 0.001
Models adjusted for time, age (in 10 year increments), race (Latina or White vs. Black), education (< high 
school vs. high school or more) and study site (Brooklyn as reference)
Three women did not have study visits with behavioral data subsequent to the WMH-CIDI assessment
a Exchanged money for sex/drugs/shelter, multiple male partners, or receptive anal sex
b Any illicit drug use or consumption of > 7 National Institute on Alcohol Abuse and Alcoholism standard 
drinks per week
12-month DSM-IV diagnostic category Risky sexual  behaviora 
16% (166) of women
OR (95% CI)
Risky alcohol/drug  useb 
38% (390) of women
OR (95% CI)
Mood disorders
 Major depressive disorder 5.96 (2.78, 12.77)*** 4.43 (1.89, 10.39)**
 Dysthymia 4.19 (1.58, 11.15)** 1.79 (0.58, 5.56)
 Bipolar I and II disorders 13.57 (4.06, 45.34)*** 1.70 (0.39, 7.45)
Any mood disorder 5.70 (2.75, 11.86)*** 4.52 (2.02, 10.12)***
Anxiety disorders
 Panic disorder 4.67 (1.40, 15.65)* 2.80 (0.67, 11.69)
 Agoraphobia 1.99 (0.49, 8.17) 1.96 (0.41, 9.42)
 Specific phobia 2.54 (1.20, 5.38)** 1.78 (0.78, 4.08)
 Social phobia 3.74 (1.57, 8.91)*** 2.14 (0.80, 5.71)
 Generalized anxiety disorder 1.87 (0.57, 6.06) 3.04 (0.87, 10.62)
 Posttraumatic stress disorder 2.30 (1.01, 5.20)* 1.58 (0.62, 4.02)
 Obsessive–compulsive dis. 5.26 (1.88, 14.69)** 1.34 (0.38, 4.79)
 Separation disorder (adult) 3.40 (1.03, 11.21)* 1.72 (0.41, 7.29)
Any anxiety disorder 4.46 (2.26, 8.78)*** 2.84 (1.40, 5.76)**
Substance use disorders
 Alcohol abuse 6.20 (1.17, 32.80)*** 69.05 (8.85, 538.76)***
 Alcohol dependence 9.09 (1.67, 49.64)*** 51.14 (6.44, 406.17)***
 Drug abuse 14.28 (4.30, 47.14)*** 67.93 (15.26, 302,36)***
 Drug dependence 11.40 (3.79, 34.30)*** 20.79 (5.62, 76.83)***
Any substance use disorder 6.60 (2.64, 16.50)*** 48.53 (16.99, 138.53)***
Co-occurring psychiatric + substance use disorders
 Any mood + any substance use 15.88 (4.35, 57.92)*** 23.42 (4.87, 112.58)***
 Any anxiety + any substance use 9.54 (3.20, 28.44)*** 16.96 (4.66, 61.68)***
Any psychiatric + any substance use 10.43 (3.67, 29.67)*** 19.57 (5.68, 67.42)***
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significant associations with most anxiety disorders includ-
ing panic, specific phobia, social phobia, PTSD, OCD, and 
adult separation anxiety disorder. Agoraphobia and gen-
eralized anxiety disorder were not associated with subse-
quent sexual risk behaviors. Women with any psychiatric 
disorder and co-occurring substance use disorder were over 
10 times as likely to engage in risky sexual behaviors [OR 
10.4 (3.7–29.7)], and women with any mood disorder and 
co-occurring substance use disorder were over 15 times as 
likely [OR 15.9 (4.4–57.9)].
By definition, strong associations were expected between 
substance use disorders and the subsequent occurrence of 
HIV drug and alcohol risk behaviors, and these are evident 
in Table 5. However, women with any mood disorder or 
any anxiety disorder also were more likely to engage in 
HIV drug and/or alcohol risk behaviors than others [OR 4.5 
(2.0–10.1), and OR 2.8 (1.4–5.8), respectively].
Discussion
Results from this investigation confirm those of the only 
other large scale assessment of behavioral health disorders 
among adults living with HIV, which was conducted almost 
three decades ago. The lifetime and 12-month prevalence of 
behavioral health disorders in this US cohort study of HIV-
positive women far exceeded that of the general population 
of US women, with mood disorders, anxiety disorders, and 
substance use disorders being two- to three-fold more com-
mon in our cohort. Also, the number of DSM-IV disorders 
was higher in our cohort than in the general US women’s 
population, with 23% having 3 or more 12-month disorders 
compared to only 7% in the general population. Another 
noteworthy difference was in the distribution of lifetime 
disorders, with substance use disorders being second most 
common in our cohort, while they were least common in the 
general women’s population.
This study also found a high degree of comorbidity across 
mood disorders, anxiety disorders, and substance use disor-
ders. This has been noted in studies of the general population 
[50, 51], but the large extent to which it characterizes HIV-
positive women is evident for the first time in our findings. 
Almost all women with lifetime mood disorders had co-
occurring lifetime anxiety disorders (87%) while over two-
thirds (68%) also had lifetime substance use disorders. Thus 
the occurrence of no behavioral health disorders or only one 
disorder was uncommon in this longitudinal study cohort. 
Among women with current 12-month disorders, the large 
majority with mood disorders also had a co-occurring anxi-
ety disorder (80%), and of those with 12-month substance 
use disorders, almost two-thirds (61%) had a co-occurring 
anxiety disorder. This extremely high level of comorbid-
ity requires complex treatment protocols and has negative 
prognostic implications for psychological health, medical 
well-being, and longevity [52, 53].
We found that sociodemographic characteristics includ-
ing education, income, being Black, and being Latina were 
negatively associated with likelihood of behavioral health 
disorders which mirrors prior CIDI research on the general 
population [8]. Employed women were less likely to have a 
recent behavioral health disorder, which parallels the well-
established negative relationship between behavioral health 
disorders and employment [54].
Finally, this study documented significant associations 
between behavioral health disorders and HIV sexual and 
drug use risk behaviors in the 3 years following diagnostic 
assessment. Risky sexual behaviors were more likely among 
women with any 12-month disorder, and were especially 
likely among women with diagnoses of bipolar disorder or 
drug use disorders. In addition, a 12-month diagnosis of 
co-occurring mood disorder with substance use disorder or 
co-occurring anxiety disorder with substance use disorder 
increased the likelihood of subsequent risky drug and alco-
hol use. Drug and alcohol risk behaviors can be associated 
with sexual risk behaviors, both because women exchange 
sex for material goods and because decision making capacity 
is diminished when under the influence. Thus, our results 
suggest that interventions addressing behavioral health may 
also prevent subsequent HIV risk behaviors. For example, it 
may be beneficial to tailor HIV risk reduction interventions 
for women with disorders in which impulse control can be 
problematic, such as bipolar and substance use disorders 
[55], since these had the highest odds ratios for HIV trans-
mission behaviors. Similarly, interventions might effectively 
be tailored for women with high levels of negative affect and 
associated risk taking [56], such as major depression and 
obsessive–compulsive disorder [57], since our findings also 
showed moderately high odds ratios for these disorders and 
HIV risk behaviors.
A number of study limitations should be noted. The study 
cohort may not be generalizable to the US population of 
women living with HIV, and the cohort may not represent 
younger women or those who are not engaged in HIV care. 
In addition, space limitations prevent us from identifying 
associations between behavioral health disorders and fac-
tors such as income, race, education, and other demographic 
variables in the NCS-R comparator data. Another limitation 
is use of self-report for key study variables such as frequency 
and types of HIV risk behaviors. WMH-CIDI assessments 
were not available for the entire cohort, and this may have 
biased our results, especially those related to women who 
spoke only Spanish or those who were employed. Finally, 
we do not consider the effects of receiving treatment for 
behavioral health disorders or HIV/AIDS since these are 
the subject of a separate manuscript. Study strengths include 
the large number of participants, the multisite nature of the 
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cohort, the diversity of geographic site locations, inclusion 
of a comparison population, and use of diagnostic interviews 
instead of screening tools.
The major implication of these results is the critical 
need for integrated health and behavioral health care and 
the importance of addressing the challenges currently faced 
in organizing and providing it to women living with HIV 
[58]. Studies have shown that screening HIV-positive adults 
and referring them to mental health and substance abuse 
treatment is largely ineffective [59], especially when psy-
chiatric disorders and substance use disorders co-occur [60]. 
Moreover, the high rate of co-morbidity among HIV-posi-
tive women may make screening for discrete conditions an 
ineffective approach. Further, because women from diverse 
cultures experience and express behavioral health symp-
toms and role impairment differently [61, 62], screening 
and assessment must also be sensitive to African American, 
Hispanic/Latina, and other cultures [63, 64], as well as to the 
intersection of trauma with poor mental health and substance 
use in the lives of many HIV-positive women [65, 66].
The fact that women living with HIV have multiple co-
occurring behavioral health disorders of high severity poses 
serious challenges to clinicians seeking to provide coordi-
nated care. The term “health complexity” has been coined 
to refer to individuals with multiple co-morbid medical and 
behavioral health conditions whose care is complicated by 
personal and social factors such as housing, ethnicity, social 
support, and poverty, as well as by health system factors 
such as inadequate insurance coverage, gaps in specialty 
care, and segregated medical and behavioral health treat-
ment [67, 68]. This characterization fits our study population 
especially well, and calls attention to specific challenges. 
One such challenge is a lack of evidence-based treatment 
options for people with co-occurring substance use disor-
ders, mood disorders, and anxiety disorders. Research shows 
that treating only one of these disorders does not improve 
the others, and that when only one is treated, significant 
distress and disability typically remain [52, 69]. An alter-
native approach is concurrent treatment, in which separate 
therapies are delivered at the same time. For example, stud-
ies support combining cognitive behavioral therapy for 
substance use disorders with exposure therapy or cogni-
tive restructuring for anxiety disorders [69]. Research also 
supports the use of integrated treatment approaches, where 
services that target multiple conditions simultaneously are 
delivered in a coordinated fashion. For example, a recent 
trial combining sertraline and naltrexone for treating co-
occurring depression and alcohol dependence was effective 
in reducing depression and promoting alcohol abstinence 
[70]. However, development and evaluation of these models 
are in relatively early stages, meaning that we lack effective 
treatments for co-occurring behavioral health disorders [52], 
especially among women [71].
A second level of challenges involves integrating medi-
cal and behavioral health treatment in the face of multiple 
co-occurring conditions of each type along with personal 
and health system factors. Here again, there are promising 
models that can be applied to HIV-positive women with 
multi-morbidities. One is the collaborative care model in 
the primary care setting, where case managers or nurse prac-
titioners work with primary care providers, mental health 
professionals, and substance use treatment specialists in a 
patient-centered, socioecologically focused approach that 
incorporates community and health system factors [72, 73]. 
Another model is integrated complex case management, 
which involves the longitudinal, relationship-based use of 
biopsychosocial and health system-based care plans that 
are complexity-focused, with few handoffs, and escalation 
of care as well as discharge based on clinical, functional, 
and cost outcome measurement [68]. Application of these 
models in the HIV field is relatively new, but they offer great 
promise [74–76], especially when designed to also address 
HIV-positive women’s key structural determinants includ-
ing violence against women and economic insecurity [26].
In addition to the human costs of co-occurring HIV 
infection and behavioral health disorders, the financial 
costs are considerable. One recent analysis of patients in 
the Kaiser Permanente Northern California integrated health 
care system [77], reported that mean total healthcare costs 
were higher in HIV-positive patients who were diagnosed 
with psychiatric disorders and substance use disorders (per 
patient per year average of $32,881) compared to HIV-pos-
itive patients without these comorbidities (per patient per 
year average of $29,142), and that this difference remained 
significant after controlling for confounding individual char-
acteristics. Taking this one step further, the strong associa-
tion between having psychiatric disorders and substance use 
disorders and engaging in HIV risk behaviors increases the 
chances of viral transmission and creation of new infections, 
while lessening the positive potential of treatment as preven-
tion [78], incurring additional societal costs and individual 
burdens.
We conclude that the development, testing, and diffusion 
of evidence-based, culturally sensitive, trauma-informed 
models of complex, integrated physical and behavioral 
health care should be a key public health strategy for HIV 
prevention and control. Also needed is further investiga-
tion of how race/ethnicity, income, education, poverty, and 
trauma affect the experience and expression of behavioral 
health disorders among women living with HIV. Finally, 
the impact of treatment for mental health and substance use 
disorders on the likelihood of engaging in HIV risk behav-
iors requires further exploration, in order to more effectively 
integrate behavioral health and antiretroviral therapies.
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